You bring the model, the market, and the clinical thinking. We engineer the lab integrations, physician review workflow, insight layer, and HIPAA-grade infrastructure underneath it, as one system rather than five vendors stitched together after launch. You own the product, the code, and the roadmap.
Panels, categories & data sources we build against
Consumer biomarker testing stopped being a curiosity the moment a single player raised at a multi-billion-dollar valuation on a membership model. Lab access is no longer the barrier, because the infrastructure now exists as APIs. What separates operators today is engineering: whether the platform underneath turns results into something a member pays for again next year. That is the part we are hired to build.
$4.08B
Global direct-to-consumer laboratory testing market size entering 2026, the category your platform sells into.
8.77%
Compound annual growth taking the market to roughly $8.69B by 2035, more than doubling within a decade.
47%
More than 47% of global DTC testing revenue sits in North America, which is why most builds launch U.S.-first.
$2.5B
Valuation at its $298M Series B in November 2025, after running 50M+ lab tests since 2023 on partner infrastructure.
Sources: Precedence Research, direct-to-consumer laboratory testing market (2026); TechCrunch and Function Health announcement, November 2025. Market figures are third-party estimates and vary by methodology; treat them as directional rather than guaranteed.
None of these show up in a pitch deck. They show up in month four, when the first hundred paying members are already in the system and the architecture can no longer be changed cheaply. We have watched each one play out, so we now scope and build against them from the first sprint rather than discovering them live.
Sandbox credentials, result-format validation, and requisition mapping run on the lab partner's timeline, not yours. Teams that treat it as a two-week API task routinely lose two months and push the whole launch.
Two labs report the same analyte under different names, units, and reference ranges. Without a normalization layer in the data model from day one, every new lab partner becomes a fresh integration project instead of a configuration change.
Clinical sign-off is not a checkbox, it is a queue with flagging, escalation, state-by-state licensing logic, and an audit trail. Retrofitting it after results are already flowing means rebuilding the release pipeline under live members.
The first panel sells itself. The renewal does not. Without trend tracking, retest prompts, and insight that changes between panels, the product is a one-time purchase wearing a subscription price tag.
HIPAA handling, consent capture, retention policy, and vendor BAAs shape the schema, the logging, and the hosting decision. Discovering that in week 30 means re-architecting storage, not adding a policy page.
Generic "your cholesterol is high" output gets ignored. Insight only earns renewals when it references that member's own trend, their wearable data, and what changed since the last panel, which requires the data model to support it.
It is a membership health product that orders lab panels on a member's behalf, routes every result through licensed physician review, and turns the numbers into an ongoing, trackable picture of that person's health rather than a one-off PDF they never open again.
Three things separate it from a standard diagnostic lab app. It manages a recurring relationship instead of a single transaction, which changes the entire retention model. It layers interpretation and trend detection on top of raw values, so the third panel is more valuable than the first. And it typically ingests wearable and CGM data so lifestyle signals can be correlated against biomarker movement, which is what makes an insight specific enough to act on.
Function Health, Superpower, InsideTracker, and Marek Health are the clearest examples of the category operating at scale. None of them own their labs. They own the ordering layer, the clinical workflow, the interpretation engine, and the membership relationship, which is precisely the software we build.
Everything else on this page is detail. These five are what we are actually hired to get right.
The architecture underneath changes significantly depending on which model you are running, so we settle this before development starts rather than rewriting the build halfway through. Each card below names what we would tackle first for that model.
A broad 80 to 100+ biomarker panel on an annual membership, with physician review and a consumer dashboard as the core product. The widest surface area to build, and the model with the strongest renewal economics when trend tracking is done properly.
Built around a continuous glucose monitor, pairing real-time glucose streams with food logging and metabolic scoring. The engineering weight shifts away from lab integration toward high-volume time-series ingestion and real-time processing.
Specialized around methylation-based biological age testing. A narrower panel catalog with premium pricing, where product value sits almost entirely in how well the score is explained and tracked across repeat tests.
Lab testing paired with ongoing physician-managed protocols such as TRT. Requires deeper clinical workflow, prescription handling, and follow-up scheduling than a pure testing product, plus tighter state licensing logic.
A white-labeled version sold to employers and health plans, priced per enrolled employee. Adds org hierarchies, cohort reporting, eligibility files, and aggregate dashboards that never expose an individual’s results.
A high-touch build pairing testing with direct physician access, white-glove onboarding, and scheduled consults. Lower volume, far higher revenue per member, and the model most dependent on scheduling and messaging quality.
This is the structure we build to, and the order we build it in. A requisition goes out, results come back, a clinician clears them, the insight engine interprets them, and the member sees something worth renewing for. Build these layers in the wrong order and every later change gets expensive, which is why we settle the data model before we write feature code.
Places requisitions with partner labs, tracks orders through collection and processing, and pulls results back. Built to talk to multiple labs from day one so adding a partner is configuration, not a new integration project.
Maps every incoming analyte to one canonical identifier with consistent units, then evaluates it against configurable optimal and clinical ranges that can differ by age, sex, and panel. This is the layer that makes multi-lab operation possible.
Routes each panel to a clinician licensed in the member's state, surfaces flagged and critical values first, captures sign-off, and gates release to the member. Every action is written to an immutable audit trail.
Turns cleared results into plain-language explanation, detects meaningful movement across repeat panels rather than reacting to a single out-of-range value, and correlates biomarker trends against wearable and CGM signals.
Three distinct interfaces on one backend: the member app where results and trends live, the clinician console built for review throughput, and the admin panel for panel catalog, lab partners, ranges, and membership operations.
A complete biomarker platform build, broken into the pieces we own. Most engagements start with the first four, then expand once real members and real results are moving through the system. You can hand us all nine or slot us into the ones your team is not set up to cover.
Direct or aggregator-based integration covering requisition placement, order status, result retrieval, and multi-lab normalization into one schema.
The clinical console: review queues sorted by urgency, flagging rules, critical-value escalation, sign-off capture, and a tamper-evident audit trail.
An interpretation layer that converts cleared biomarker values into plain-language, trend-aware guidance specific to that member's history.
Ingestion pipelines for device data, normalized and correlated against biomarker movement so lifestyle signals and lab results sit on one timeline.
Recurring billing, plan tiers, add-on panel purchases, upgrades, dunning, and the renewal logic that the whole business model depends on.
Compliance built into the schema, logging, and hosting rather than bolted on before launch, with vendor BAAs and retention policy handled up front.
Member, clinician, and admin experiences designed around their real workflows, because a clinician reviewing 200 panels needs nothing the member app offers.
Operational dashboards covering retention, retest rates, review turnaround, and cohort outcomes, plus the aggregate reporting B2B buyers ask for.
Ongoing iteration as you add panels, labs, and markets, with monitoring and on-call cover for the integrations that break quietly.
A biomarker platform is really three products sharing one backend, and we build all three. Teams that scope only the member app end up running clinical review and operations out of spreadsheets within a month of launch, so we plan the clinician and admin surfaces into the same delivery rather than treating them as phase two.
What the paying member sees. This is where renewals are won or lost, so every feature here exists to make the next panel feel more valuable than the last one.
Built for throughput. A clinician clearing 200 panels a day needs sorting, batching, and escalation, not the member's dashboard with an approve button added to it.
The tooling that keeps you off spreadsheets. Panels, ranges, lab partners, and memberships all need to be editable by your ops team without a developer in the loop.
Not a launch checklist. These decisions shape the data model and the hosting architecture, which is why they belong in the first sprint rather than the last one.
Six stages, each one a distinct piece of engineering we deliver. The two your members never see, normalization and clinical review, are the ones that decide whether everything they do see actually works, and they are where most of our build effort goes.
Member creates an account, passes identity verification, gives informed consent, and selects a membership tier or panel. Consent version is stored against the account for audit purposes.
The platform places a requisition with the partner lab and routes the member to a draw site or ships an at-home collection kit, tracking the order through every status change.
Results come back and are mapped to canonical analytes with consistent units, then evaluated against the member's applicable reference ranges and their own prior panels.
A licensed clinician reviews the panel, with flagged and critical values surfaced first. Nothing reaches the member until sign-off is recorded and written to the audit trail.
Cleared results are released alongside plain-language explanation, trend comparison against prior panels, and correlation with the member's connected wearable data.
Scheduled retests build the longitudinal record that makes each panel more useful than the last, and it is this compounding history that drives renewal rather than the first result.
Real engagement ranges, not a "contact us for pricing" wall. What moves the number is how many lab and device integrations we have to build and how wide your compliance surface is across states and countries. We scope both in the first conversation so the estimate you get is one we can stand behind.
$80K – $150K
The narrowest scope that can take real members, run real panels, and prove the model before you spend more.
$200K – $400K
The full consumer product, including the AI insight layer and wearable correlation that renewals actually depend on.
$400K+
For operators selling into employers and health plans, or launching across multiple regulatory regions at once.
These are honest planning ranges based on comparable healthcare and diagnostics builds, not fixed quotes. Lab partner onboarding sits outside our control and is frequently the schedule risk, so we scope it first and build the rest around it. You get a fixed, itemized estimate after the first scoping session, before any contract is signed.
Bring us your model and we will map the lab integrations, clinical workflow, and compliance surface it needs, then hand you a scoped estimate with a realistic timeline. No obligation, and the scoping document is yours to keep whether or not you build with us.
Book a Free Strategy CallEvery item here shapes the schema, the logging, or the hosting decision. That is why we scope compliance in the first sprint rather than treating it as a pre-launch review, and why each requirement below is paired with what we actually implement.
Any platform touching identifiable health data needs compliant storage, transmission, access control, and signed BAAs with every vendor in the chain, including your cloud provider.
The lab performing your testing must hold CLIA certification. Your platform does not need its own, but it does need to prove it only routes orders to certified partners.
On March 31, 2025 a federal court in the Eastern District of Texas vacated the FDA's Laboratory Developed Tests rule in full, holding that LDTs are services governed under CLIA rather than FDA-regulated devices.
A clinician reviewing a member's panel generally needs to be licensed in that member's state, which turns review assignment into a rules engine rather than a round-robin queue.
Consent must be captured, versioned, and provable, and retention rules differ by state and country. Both belong in the core data model, not in a policy document.
UK GDPR and CQC considerations in Britain, DHA or MOHAP licensing plus data-residency requirements in the UAE, each of which affects where data can physically live.
Idea Usher is a software development partner, not a law firm or regulatory consultancy. We build platforms to meet the technical requirements your counsel defines and we flag the questions worth asking, but regulatory positioning, clinical policy, and licensing decisions should be made with qualified healthcare counsel in each market you enter. Regulations in this category are actively changing, including the 2025 LDT ruling referenced above.
Architecture and feature blueprints informed by how each of these companies approaches the category. These are reference points for scoping your own product, not clone scripts, and every description below is based on publicly available information.
A comprehensive 100+ biomarker membership platform with physician review, running lab work through existing Quest Diagnostics infrastructure rather than owned labs. Raised a $298M Series B at a $2.5B valuation in November 2025, having run over 50 million lab tests since 2023.
A biomarker testing membership built around a streamlined panel-selection experience and a content-led acquisition funnel, positioning itself as a consumer-friendly entry point into comprehensive testing.
Combines blood biomarkers with DNA data and fitness-tracker signals, presenting results as a composite score alongside targeted nutrition and lifestyle recommendations.
A continuous glucose monitoring product pairing real-time glucose streams with food logging, turning a medical device data feed into a daily-engagement consumer metabolic product.
A hormone optimization platform pairing lab testing with physician-managed treatment protocols, operating closer to a clinical service than a pure consumer testing product.
An epigenetic testing company specializing in methylation-based biological age and longevity biomarkers, a narrower and more premium slice of the category with strong repeat-testing economics.
Idea Usher is not affiliated with, endorsed by, or partnered with Function Health, Superpower, InsideTracker, Levels Health, Marek Health, or TruDiagnostic. Company descriptions are drawn from publicly available information and are included for reference and benchmarking purposes only.
Most operators run three or four of these at once, and each one needs different billing, entitlement, and reporting logic underneath it. Tell us which you are planning and we build the system to support them from day one, rather than bolting a second revenue line onto a platform that only ever expected the first.
The recurring line the whole model rests on, typically billed annually and covering a defined panel plus platform access. Consumer memberships in this category commonly land in the $350 to $500 per year range.
Specialty panels bought à la carte beyond the core membership, such as hormone, epigenetic age, or advanced cardiovascular. High margin because acquisition is already paid for.
White-labeled deployment sold to employers and health plans, usually priced per enrolled employee. Longer sales cycle, but far more predictable revenue than consumer acquisition.
Paid consults for members who want to talk through results directly with a clinician. Also the natural upsell moment for treatment-led platforms operating hormone or metabolic protocols.
A higher subscription tier unlocking deeper trend analysis, personalized protocols, or more frequent retesting. Works best once you have enough longitudinal data to make the tier feel worth it.
Commissions from supplement, wearable, or wellness partners recommended through the platform. Worth structuring carefully, since undisclosed incentives erode the clinical trust the product depends on.
Lab integration starts in week one, not week twenty, because it is the only part of the schedule that depends on somebody else's timeline. Everything else is built around it.
We map your model, target markets, panel catalog, and clinical workflow, then define the compliance surface before a line of code is written. You leave this phase with a scoped estimate and a written architecture direction.
Runs in parallel from day one. Sandbox credentials, requisition formats, and result-schema validation with your lab partner or aggregator, because this is the dependency that most often decides the launch date.
Three interfaces designed against their real workflows, plus the data model for analyte normalization, reference ranges, consent, and audit. Getting the schema right here is what keeps later changes cheap.
Member app, clinician console, admin tooling, billing, and the ingestion and normalization pipeline, built in two-week sprints with a working demo environment you can log into at the end of each one.
Wearable and CGM pipelines, the AI interpretation and trend-detection engine, and any additional lab partners. This is where the product stops being a results viewer and becomes a longevity platform.
Encryption verification, access-control testing, audit log validation, retention policy enforcement, penetration testing, and BAA confirmation across every vendor touching PHI.
A controlled pilot with real panels through the full pipeline before public launch, then monitoring, fixes, and iteration as volume ramps. Support continues past go-live rather than ending at handover.
We pick for regulated healthcare workloads rather than novelty. Every item here has a BAA path, a deep enough hiring pool that you are never locked to us, and a track record in production systems handling protected health information. If your team already has a stack preference, we build to it.
Server-rendered for fast first loads on the marketing surface, with a rich client app behind authentication.
React Native when one codebase serves both stores, native when deep health-framework integration justifies it.
Service-oriented rather than monolithic, so the ingestion pipeline can scale independently of the member app.
Relational core for clinical records with field-level encryption, plus time-series storage for high-volume device data.
Guardrailed LLM output for explanation, classical models for trend detection where determinism matters more.
Provisioned under a signed BAA, with infrastructure as code so compliance configuration is reviewable and repeatable.
A biomarker platform is mostly an integration product, which means most of our build time goes here. These are the categories we connect and the specific services we work against most often, including the aggregators that let you add a second lab or device without a second integration project.
Order placement, status tracking, and result retrieval, directly or through an aggregator that normalizes many labs at once.
Sleep, recovery, activity, and continuous glucose streams, normalized onto the same timeline as lab results.
Recurring billing, add-on purchases, dunning, and the health-specific payment methods members expect to use.
EHR interoperability, e-prescribing, and telehealth for platforms that pair testing with treatment or consults.
Working with a lab, device, or EHR that is not on this list? If it exposes an API, we can integrate it.
The differences that matter in a regulated healthcare build are rarely about hourly rate. They show up in whether anyone on the team has integrated a lab before, and whether compliance was designed in or discovered late.
| Capability | Freelancers | Generic Agencies | Idea UsherHealth-tech team |
|---|---|---|---|
| Lab integration experience | Rare | Occasionally | Diagnostics pipelines built before |
| HIPAA designed into the schema | Usually retrofitted | Checklist at the end | First-sprint architecture decision |
| In-house AI/ML engineers | Subcontracted | Often outsourced | On the same delivery team |
| Mobile, web & backend in parallel | Sequential | Usually | 250+ team, staffed in parallel |
| Clinical workflow understanding | No | Rarely | Review queues & audit trails by default |
| Continuity if a developer leaves | Project stops | Depends on bench | Documented, multi-engineer coverage |
| Post-launch ownership | Ends at delivery | Separate contract | Monitoring & iteration after go-live |
| Verifiable track record | Portfolio only | Varies widely | 4.9/5 on Clutch, 1,000+ projects |
Different starting points, same underlying platform. What changes is which layer you need built first and how wide the compliance surface has to be on day one.
Entering the category with a differentiated angle and needing a compliant MVP fast enough to validate it.
Already delivering testing in person and wanting the membership platform and app layer around it.
Holding CLIA certification and lab capacity, missing the consumer-facing product that monetizes it.
Adding biomarker testing to a benefits offering, with cohort reporting and eligibility handling built in.
Extending an existing membership base into testing, where the acquisition cost is already paid.
Running treatment protocols that need lab testing, monitoring, and prescription workflow in one system.
Piloting preventive testing programs and needing de-identified population-level reporting.
Launching the model outside the U.S., where data residency and licensing shape the architecture.
Biomarker platforms fail on the unglamorous parts: integration reliability, clinical workflow, and compliance that was designed in rather than discovered late. That is the part we are good at.
Tell us your model and target markets. You will leave the call with a clear picture of the lab integrations, clinical workflow, and compliance surface your build needs, plus a realistic timeline and cost range.
Book a Free Strategy CallA focused MVP covering lab integration, physician review, and a member app typically runs $80,000 to $150,000. A full platform adding wearable and CGM integrations, an AI insight engine, and employer or B2B portals ranges from $200,000 to $400,000 and up. The two variables that move the number most are how many lab and device integrations you need and how wide your compliance surface is across states and countries.
A production-ready MVP typically takes four to six months. A full-featured platform with wearable integrations, an AI insight layer, and employer or B2B portals runs eight to ten months. Lab integration is usually the critical path, because partner onboarding, sandbox access, and result-format validation depend on the lab's timeline, not yours.
Almost nobody in this category builds their own lab. You integrate with CLIA-certified partner labs and networks, either directly or through an aggregator that normalizes ordering and results across many labs. Function Health, for example, runs its testing through existing Quest Diagnostics infrastructure rather than owning collection sites. Your platform's job is ordering, routing, result normalization, review, and interpretation.
In practice, yes. In most U.S. states a lab test ordered for a consumer needs a licensed ordering clinician, and releasing results without clinical review creates both regulatory exposure and a trust problem with members. Treat physician review and sign-off as a core workflow with queues, flagging, escalation, and a full audit trail, not as an optional feature you add later.
The regulatory picture shifted in 2025. On March 31, 2025, a federal court in the Eastern District of Texas vacated the FDA's Laboratory Developed Tests final rule in its entirety, finding that LDTs are services regulated under CLIA rather than devices under FDA jurisdiction. That reduces near-term FDA exposure for the testing itself, but your software can still cross into medical device territory depending on the claims it makes, which is why claim language and feature scope should be reviewed with qualified counsel before launch.
Yes, and it is the layer that separates a longevity platform from a lab-results app. The reliable pattern is to use AI for interpretation and contextualization after a physician has reviewed and cleared results: translating values into plain language, detecting meaningful trends across repeat panels, and correlating biomarkers with wearable data. It should surface what a clinician already signed off on, never replace that sign-off.
At minimum: member onboarding with identity verification and consent capture, one lab integration covering order placement and result retrieval, a physician review queue with sign-off, a member dashboard with reference ranges and trends, and recurring billing. Wearable integrations, AI insights, and B2B portals are the second release. Shipping a narrower scope that handles real members and real results beats a broader scope that is still in QA.
North America accounts for more than 47% of global direct-to-consumer lab testing revenue and remains the deepest market, with the United Kingdom and the UAE as strong secondary launches given rising consumer demand for proactive testing. Each market carries its own regulatory scoping: HIPAA and state telehealth licensing in the U.S., UK GDPR and CQC considerations in Britain, and DHA or MOHAP licensing and data-residency rules in the UAE.
Whether you are entering the category fresh or already running testing and need the platform built around it, the scoping conversation is free and the output is yours to keep either way.
Ed-Tech
We developed an innovative exam preparation app, equipped with features including a Content Management System (CMS) and robust user authentication. Our user-friendly design simplifies content search and filtering, enabling seamless progress tracking and interaction with interactive learning tools. With scalability and reliability at its core, the app ensures a secure learning environment through encryption and regular audits.
Downloads
Blockchain Trading Platform
Downloads
Gym Membership App
Downloads
Booking App
Ticketbox is developed with user convenience in mind, boasting an intuitive interface and seamless functionalities for effortless booking management, ticket viewing, and tracking of booking history. Our integration of secure payment gateways ensures peace of mind, while real-time updates keep users informed every step of the way.
CEO | Carpooll
CEO | Deluxe Days
CEO | LogiTrac
CEO | ElecGlide
CEO | RhythmoReunion
CEO | Gemstone Gallery
CEO | SoulSingles
CEO | Allayya
CEO | Vezita
“The team was great to work with, stayed on track, and exceeded our expectations.”
“They demonstrated a thorough understanding of our project requirements and provided innovativ…
Talk to our experts and get the best solutions
Get in touch now
Congratulations on taking the first step towards taking your business to new heights!
We are ready to take you there.
We will soon contact you for more details.
